title: Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors.
abstract: BACKGROUND
  Gastrointestinal stromal tumors (GISTs) historically were grouped with leiomyosarcomas (LMSs) based on their morphologic similarities; however, recently, GIST was established unequivocally as a distinct type of sarcoma based on its molecular features and response to imatinib treatment.
  
  
  METHODS
  To gain further insight into the genomic differences between GISTs and LMSs, the authors mapped gene copy number aberrations (CNAs) in 42 GISTs and 30 LMSs and integrated the results with gene expression profiles.
  
  
  RESULTS
  Distinct patterns of CNAs were revealed between GISTs and LMSs. Losses in 1p, 14q, 15q, and 22q were significantly more frequent in GISTs than in LMSs (P < .001); whereas losses in chromosomes 10 and 16 and gains in 1q, 14q, and 15q (P < .001) were more common in LMSs. By integrating CNAs with gene expression data and clinical information, the authors identified several clinically relevant CNAs that were prognostic of survival in patients with GIST. Furthermore, GISTs were categorized into 4 groups according to an accumulating pattern of genetic alterations. Many key cellular pathways were expressed differently in the 4 groups, and the patients in each group had increasingly worse prognoses as the extent of genomic alterations increased.
  
  
  CONCLUSIONS
  Based on the current findings, the authors proposed a new tumor-progression genetic staging system termed genomic instability stage to complement the current prognostic predictive system based on tumor size, mitotic index, and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) mutation.
authors.affiliation: Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Antti
authors.initials: A
authors.lastname: Ylipää
authors.forename: Kelly K
authors.initials: KK
authors.lastname: Hunt
authors.forename: Jilong
authors.initials: J
authors.lastname: Yang
authors.forename: Alexander J F
authors.initials: AJ
authors.lastname: Lazar
authors.forename: Keila E
authors.initials: KE
authors.lastname: Torres
authors.forename: Dina C
authors.initials: DC
authors.lastname: Lev
authors.forename: Matti
authors.initials: M
authors.lastname: Nykter
authors.forename: Raphael E
authors.initials: RE
authors.lastname: Pollock
authors.forename: Jonathan
authors.initials: J
authors.lastname: Trent
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
mesh_terms: D055028:Comparative Genomic Hybridization; D056915:DNA Copy Number Variations; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000235:genetics* / Q000401:mortality; D020869:Gene Expression Profiling; D042822:Genomic Instability; D006801:Humans; D007890:Leiomyosarcoma / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015398:Signal Transduction
references.citation: Am J Pathol. 1998 Sep;153(3):985-90
references.pmid: 9736047
references.citation: Nat Genet. 2000 May;25(1):25-9
references.pmid: 10802651
references.citation: Science. 2003 Jan 31;299(5607):708-10
references.pmid: 12522257
references.citation: Lab Invest. 2001 Feb;81(2):211-5
references.pmid: 11232643
references.citation: Genes Chromosomes Cancer. 2001 May;31(1):54-64
references.pmid: 11284036
references.citation: Cancer. 2008 Oct 1;113(7):1532-43
references.pmid: 18671247
references.citation: Cancer Genet Cytogenet. 2006 Sep;169(2):94-101
references.pmid: 16938566
references.citation: Cancer Genet Cytogenet. 2000 Jun;119(2):102-8
references.pmid: 10867143
references.citation: J Clin Oncol. 2002 Jun 15;20(12):2824-31
references.pmid: 12065559
references.citation: Cancer Genet Cytogenet. 2000 Jan 1;116(1):66-73
references.pmid: 10616536
references.citation: Cancer Genet Cytogenet. 2005 Aug;161(1):20-7
references.pmid: 16080954
references.citation: Cancer Lett. 2009 Mar 8;275(1):1-8
references.pmid: 18649996
references.citation: Mutat Res. 1991 Apr;247(2):199-202
references.pmid: 2011137
references.citation: Cancer Res. 2004 Sep 1;64(17):5913-9
references.pmid: 15342366
references.citation: Cancer Cell. 2010 Jan 19;17(1):98-110
references.pmid: 20129251
references.citation: Nat Rev Neurol. 2009 Aug;5(8):419-26
references.pmid: 19597514
references.citation: Cytogenet Cell Genet. 2000;90(1-2):86-92
references.pmid: 11060455
references.citation: Ann Oncol. 2006 Sep;17 Suppl 10:x280-6
references.pmid: 17018739
references.citation: Mod Pathol. 2003 Aug;16(8):778-85
references.pmid: 12920222
references.citation: Cell. 1990 Jun 1;61(5):759-67
references.pmid: 2188735
references.citation: Cancer Res. 2006 Sep 15;66(18):8984-93
references.pmid: 16982739
references.citation: Cancer Res. 2000 Jul 15;60(14):3899-903
references.pmid: 10919666
references.citation: Biostatistics. 2004 Oct;5(4):557-72
references.pmid: 15475419
references.citation: Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3414-9
references.pmid: 17360660
references.citation: J Natl Compr Canc Netw. 2007 Jul;5 Suppl 2:S1-29; quiz S30
references.pmid: 17624289
references.citation: Bioinformatics. 2007 Apr 1;23(7):892-4
references.pmid: 17267432